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Considering evidenCe From HealtH eConomiCs WitHin immunization 
deCision-making - a semi multiPle Criteria deCision aPProaCH using 
tHe deCide tool
Ultsch B, Wichmann O, Harder T
Robert Koch Institute, Berlin, Germany
BAckground: mmunization decision-making (IDM) should draw on high qual-
ity evidence from various sources such as health economics (HE). Objective of 
this study was to test the applicability of a framework that enables a systematic, 
transparent, and evidence based IDM based on multiple criteria. Method: We 
applied the ‘Evidence to Decision (EtD) Framework’ developed by the ‘Developing 
and Evaluating Communication Strategies to Support Informed Decisions and 
Practice Based on Evidence’ (DECIDE) collaboration to the example of vaccination 
against pneumococcal-disease (PD) in adults and utilized HE evidence from a mod-
eling study for Germany. We tested how EtD criteria can be operationalized for the 
development of a specific IDM on which HE was expected to have a strong impact. 
A panel of members of the Methods-Working-Group of the German standing com-
mittee on vaccination (STIKO) was asked to use the EtD framework and judge on its 
applicability and usefulness for IDM. results: Data from the HE model were used 
to inform one out of six criteria (disease-burden, evidence quality, magnitude of 
effects, balance of effects, cost-effectiveness, acceptability) of the EtD framework. 
Since two vaccine-types (23-valent polysaccharide and 13-valent conjugate vac-
cine [PPSV23, PCV13]) were compared in the HE model, judgement options for the 
HE criterion were: ‘favors PPSV23’; ‘favors PCV13’; ‘favors sequential vaccination 
PCV13&PPSV23’; ‘does not favor either’; ‘favors no vaccination’. Panel-members 
reported the usefulness of the EtD framework for IDM on PD vaccination, especially 
regarding the integration of HE result-figures. discussion: The EtD framework 
seems very suitable to consider HE in evidence based IDM even in a complex 
situation where multiple vaccination strategies are compared. It’s in particular 
helpful to communicate HE results-figures to non-economists and supports trans-
parency in IDM. In the project ‘Standardization of healTh Economic Evaluations 
of vaccINes in Germany’ (STEErING) the integration of HE in IDM will be further 
explored.
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imPaCt oF deCision making Based on tHe matCHing tHe Quality oF tHe 
early Warning indiCators in ColomBia during 2013 – 2014 BetWeen 
Private and PuBliC iPs and tHe Quantity oF aFFiliates By regimen
Ordoñez Castillo JA, Garcia Pulido IJ
Universidad de los Andes, Bogota, Colombia
oBjectives: The objective of the present study was assess the impact of the 
performance evaluation, in terms of quality of the early warning indicators in 
Colombia during 2013 – 2014 between private and public IPS and the quantity of 
affiliates. The quality has been established as a key attribute in the comprehensive 
health care, which under the General System of Social Security in Health(SGSSS) 
in the Act100 of 1993 and the reforms of Decree1011 of 2006 and Resolution1446 
of the same year, was designed and implemented the policy of the system of 
warranties of quality in health care, in terms of quality of the early warning 
indicators(EWI). Methods: A GLM and matching analysis comparing the quality 
in terms of timeliness and accessibility of health(TAH) care in the health insti-
tutions by department between 2013-2014 is proposed, taking into account the 
participation of affiliates in the contributory and subsidized regimen(CR-SR), in 
order to show that the number of members of the SGSSS at the departmental level 
is not necessarily determined by the increased presence of IPS or health centers 
or by the quality results of TAH. results: The period studied, after running nine 
models of linear regression intertwined variables mentioned above (n_obs= 33), it 
was shown that members of the SR(SR”n2013= 22669543;n2014= 22882669”;&;CR”
n2013= 20150266;n2014= 20760123”)had a correlation of 30.63%compared to public 
regardless of private-IPS , while the worst correlation 7.54 %was manifested in 
the SRmembers attending Pr-IPS, since a high degree of omitted variables Pu-Pr-
IPS manifests48.66%. conclusions: SR had a notable effect over the quantity 
of affiliates in the health system. Affiliates of both Regimens prefer to assist to 
pu-IPS considering that had the highest quality(EWI). This research will open the 
discussion about the relevance of quality indicators in health and their relation 
with national budget, and what will happen if Colombia implement a Universal 
Health System.
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PrevalenCe oF HePatitis C and PresenCe oF ComorBidities in sWeden: 
a nationWide PoPulation-Based register study
Büsch K, Kövamees J, Söderholm J
AbbVie AB, Solna, Sweden
oBjectives: The aim of the study was to estimate the prevalence of chronic hepati-
tis C (CHC) using Swedish nationwide register data. The secondary objective was to 
describe the presence of comorbidities compared with matched general population 
controls. Methods: Patients were identified according to international classifica-
tion codes (ICD) for hepatitis C (HCV) in inpatient care (1987–2013), day surgery and 
non-primary outpatient care (1997–2013) in the nationwide Swedish Patient Register. 
The prevalence of CHC was defined as cumulative prevalence, and calculated as 
the number of patients alive and resident in Sweden Dec 31st 2013 with a diagnosis 
listings for CHC during the study period divided by the total Swedish population 
on that date (n= 9 644 864). Five general population controls were matched by age, 
sex, and county of residence to each CHC patient. Presence of co-morbidities were 
ascertained from the same register after CHC diagnosis and compared with matched 
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inCrease arv aCCess For PlWHa in dominiCan rePuBliC tHrougH tHe 
transition From vertiCal suPPly system to an integrated national 
PHarmaCeutiCal system
Valdez C1, Barillas E2, Espinoza H1
1Management Sciences for Health, Arlington, VA, Dominican Republic, 2Management Sciences for 
Health, Arlington, VA, WA, USA
In 2010, the Ministry of Health (MoH) requested USAID for technical assis-
tance to implement interventions to improve the HIV/AIDS supply chain sys-
tem. Assessments revealed that fragmentation of the pharmaceutical system 
contributed to stock-outs and expiration of antiretroviral (ARVs) and other 
medicines and supplies used by disease control programs (DCPs). The imple-
mentation of an integrated system was proposed as the most efficient and sus-
tainable alternative to confront the HIV/AID pharmaceutical supply problems. 
Since 2011, the MoH with the support of USAID partners is integrating vertical 
DCP systems –including Tuberculosis and HIV/AIDS- into a single pharmaceuti-
cal management system (SUGEMI, in Spanish). The implementation of SUGEMI 
included: (1) an evidence-based for the design of the system and implemen-
tation of particular interventions; (2) institutional strengthening of national 
and regional implementing units; (3) legal support through Ministry and 
Presidential Decrees; (4) development and implementation of standard operating 
procedures (SOPs). Since 2014, the HIV/AIDS program has moved the ARVs from 
program specific stores to integrated warehouses; their personnel is using stand-
ardized SUGEMI formularies for requisition and delivery; and, has participated in 
national forecasting exercises leading to the procurement of quantities of ARVs, 
closer to the estimated needs of the patients. As a result of these interventions in 
2014 and 2015, the availability of ARVs has increased from 40% to a 97% in health 
facilities and 70% to a 100% in central warehouse. Simultaneous interventions in 
various pharmaceutical management components, within an integrated national 
pharmaceutical system have contributed to increase the availability of ARVs in 
the Dominican public health system.
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HealtH teCHnology assessment PraCtiCes in turkey
Demirbas AR1, Oner N1, Beyan A1, Sener O1, Turgut CG2
1General Directorate of Health Research, Ankara, Turkey, 2Johnson & Johnson, Istanbul, Turkey
The Ministry of Health of Turkey has a system that places a high value on improv-
ing health care in all areas. The Ministry has initiated a project called “Health 
Transition” which has some sub-components to provide the above-mentioned 
goal . A number of national priorities have been established for these components 
one of which is to address health technology assessment (HTA). Health technology 
covers a variety of practices including pharmaceuticals, medical devices, surgical 
methods and health systems that are used for protecting and promoting health; 
and preventing, diagnosing and curing of diseases. Health Economics and in par-
ticular HTA is also a high priority for the European Union (EU) as stated in the 15th 
article of the directive 2011/24/EU related to the application of patients’ rights in 
cross-border health care. Despite HTA being a high-value speciality, the Turkish 
health care system has just newly developed its HTA perspective. Even though 
the system has been put in place recently and somehow fragmented between dif-
ferent institutions, HTA department in Turkey has conducted some research and 
reports regarding medical devices and pharmaceuticals some of which have not 
yet been concluded. It is also an active member of European Health Technology 
Assessment Network by having roles and responsibilities in working packages and 
authorship in projects. There is however a long way to go. In this paper, current 
situation of Turkish Health Technology Assessment capacity has been discussed 
and some information has been given regarding the efforts of cohesion between 
EU and international society.
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evaluation oF average Cost-eFFeCtiveness ratios oF standards oF 
Care aCross diFFerent indiCations
Potluri R1, Ranjan S2, Khurana R2, Lele AM2, Prabhakar V2, Bhandari H2
1SmartAnalyst Inc., New York, NY, USA, 2SmartAnalyst India (Pvt.) Ltd., Gurgaon, India
oBjectives: Cost-effectiveness evaluations of new products are currently entirely 
focused on incremental cost-effectiveness ratios (ICERs) calculated over the stand-
ard of care (SoCs), and do not take into consideration the cost-effectiveness inher-
ent/implicit of the SoCs themselves. We argue that the average cost-effectiveness 
of the SoC, expressed as a ratio of the difference in costs between the SoC and no 
treatment/best supportive care (NT/BSC), to the difference in outcomes, or the 
ACER, also merits regular evaluation to enable comparison of value being derived 
from healthcare spend across indications. Methods: To compute ACERs of SoCs, 
the costs associated with the SoC, and the benefits accrued were compared with 
that of NT/BSC applicable to each indication, based on inputs derived from previ-
ously accepted NICE evaluations. This exercise was carried out over 25 different 
indications spread across cancers, endocrine disorders, infectious diseases and 
immune disorders. results: ACERs varied considerably, from a low of £717 (influ-
enza in elderly) to the high seen in Prader-Willi syndrome of £148,675 with a mean 
of £33,700 and median of £27,190. ACERs in endocrinology ranged from £25,485 to 
£148,675, oncology from £9,367 to £38,641; infectious diseases from £717 to £13,710, 
and immune disorders from £22,728 to £90,156. discussion: Evaluation of reign-
ing ACERs of the SoCs in different indications helps in: a) getting an estimate of 
the economic value of the healthcare budget being spent in particular indications, 
and across the pharmaceutical product spectrum, b) calibrating and evaluating 
currently accepted threshold ICERs; and c) providing decision-makers with data 
that encourages them to consider permitting greater leeway for new products’ 
ICER acceptability in indications where the SOC’s ICER may be at the lower end 
of the range, and conversely, to tighten limits in indications where the current 
SoC’s ACER may be at the higher end of the range, and thereby narrowing the 
range.
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atic literature review (May, 2015) to identify clinical trial evidence (i.e. randomized 
controlled trials, non-randomized controlled trials, and single-arm clinical trials) 
assessing sustained virological response rates among interferon-free and inter-
feron-containing antiviral regimens for hepatitis C. NMA require that the network 
is connected in order to facilitate adjusted indirect comparisons by which the 
treatment effect is isolated from the study effect. The study effects are estimated 
using common comparators. In the absence of common comparators, we incorpo-
rated the single-arm data directly into the Bayesian framework using simulated 
controls. The simulated controls were obtained by first modeling the reference 
treatment, and then using the constructed model to predict the most likely con-
trol outcome values given the observed trial characteristics. Using the simulated 
controls, traditional NMA methods were applied to the resulting data. results: 
Seventy clinical trial arms, including 8,997 patients, contributed to the analysis of 
sustained virological response (SVR). All interferon-free regimens were statistically 
advantageous when compared to peginterferon-ribavirin (RR> 2.00). Furthermore, 
all interferon-free regimens were statistically better than telaprevir+peginterferon-
ribavirin, boceprevir+peginterferon-ribavirin, simeprevir+peginterferon-ribavirin, 
and sofosbuvir+ribavirin (RR> 1.25). No statistical differences were observed 
between the interferon-free regimens. Given the large disparity between the two 
treatment classes, use of simulated-control NMA did not lead to large differences 
in conclusions when compared to the naïve approach; however, the magnitude of 
estimates and rankings were affected. conclusions: The use of single-arm tri-
als to assess interferon-free antivirals is common. We have shown that advanced 
statistical modeling can be used to assess the comparative efficacy new interferon-
free antiviral regimens.
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daClatasvir +asunaPrevir versus soFosBuvir/lediPasvir For tHe 
treatment oF CHroniC HePatitis C genotyPe 1 in JaPanese Patients: a 
matCHing-adJusted indireCt ComParison
Swallow E1, Kelley C1, Ristovska L1, Signorovitch JE1, Kalsekar A2, Wygant G2, McPhee F2
1Analysis Group, Inc., Boston, MA, USA, 2Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, 
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oBjectives: To compare daclatasvir and asunaprevir (DCV+ASV) versus sofosbuvir/
ledipasvir (SOF/LDV) for HCV genotype 1b in Japanese patients without nonstruc-
tural protein 5A (NS5A) polymorphisms. Methods: Individual patient data were 
available from the two Phase 3 trials of DCV+ASV conducted in Japan (BMS 026/031); 
published summary data were extracted from the one Phase 3 trial of SOF/LDV con-
ducted in Japan (Mizokami et al.). Patients treated with DCV+ASV without baseline 
NS5A polymorphisms at L31F/I/M/V or Y93H were included in the present analysis 
and were subject to the enrollment criteria reported in the SOF/LDV trial. To adjust 
for cross-trial differences, patients in the DCV+ASV trial were weighted to match 
reported summary baseline characteristics: age, BMI, gender, prior treatment experi-
ence, prior treatment response, interferon eligibility, HCV RNA level, IL28B genotype, 
cirrhosis status, alanine aminotransferase, albumin, and platelets. Sustained viro-
logic response at week 12 post-treatment (SVR12) and discontinuation due to adverse 
events (AEs) were compared between the treatments. results: Of the 363 patients 
treated with DCV+ASV, 282 had no baseline NS5A polymorphisms. Of these, 252 met 
the inclusion criteria of the SOF/LDV trial (n= 171) and were included in the analy-
sis. Prior to adjustment, the rate of SVR12 was lower among patients treated with 
DCV+ASV than SOF/LDV (95.2% vs. 100%; p= 0.004) and the rate of discontinuation 
due to AEs was higher among patients treated with DCV+ASV than SOF/LDV 
(4.8% vs. 0.0%; p= 0.004). After adjustment, both the rate of SVR12 and discontinu-
ation due to AEs were similar between patients treated with DCV+ASV and SOF/
LDV (SVR12: 99.3% vs. 100%; p= 0.398; discontinuation due to AEs: 1.3% vs. 0.0%; 
p= 0.327). conclusions: After adjustment for cross-trial differences in baseline 
characteristics, DCV+ASV and SOF/LDV were associated with similar efficacy and 
discontinuation due to AEs in the treatment of HCV genotype 1b in Japanese patients 
without NS5A polymorphisms at L31F/I/M/V or Y93H.
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ProBiotiCs signiFiCantly reduCe mortality in Preterm  
neWBorns WitH neCrotising enteroColitis: results oF large 
netWork meta-analysis
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
oBjectives: Several randomized control clinical trials have shown that Probiotics 
lower the death rates of preterm newborns with necrotising enterocolitis. However, 
most clinical guidelines do not currently support use of Probiotics. The objective 
of this study was to conduct a meta-analysis of mortality data from all available 
randomized control trials for Probiotics. Methods: A systematic literature search 
for randomized clinical trials for use of Probiotics in preterm newborns with necro-
tising enterocolitis (NEC) was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar and Cochrane. Data was collected for the study type, methods, coun-
try and key findings. Extracted study data included study design, patient charat-
certristcis and NEC related outcomes. A random effects meta-analysis model was 
developed to estimate overall odds ratios and risk ratio. A bayesian random effects 
network meta-analysis model with vague and informative priors was also devel-
oped. results: We identified 350 references and found 23 randomized trials in 7136 
newborns with 408 events. The mean size of the clinical trials was approximately 
300 patients. In the Probiotics and Placebo groups, there were 166 and 242 deaths, 
respectively. The random effects Odds Ratio for mortality for Probiotics versus 
Placebo was 0.69 (95% confidence interval 0.56 and 0.86; P= 0.0007). The random 
effects risk ratio for mortality for Probiotics versus Placebo was 0.72 (95% confidence 
interval 0.60 and 0.88; P= 0.00010). conclusions: This large meta-analysis shows 
that use of Probiotics significantly reduces the risk and odds of death in preterm 
newborns with necrotising enterocolitis. There is an urgent need for updating clini-
cal guidelines based on this cumulative evidence.
general population controls. results: In total, 49 026 patients with a HCV diag-
nosis were identified, of which 34 633 CHC patients were still alive and in Sweden 
on December 31st 2013 resulting in a CHC prevalence of 0.36% in 2013 (in males: 
0.46%; in females: 0.26%). Mean age in 2013 was 49 years (SD 12.95). Chronic liver 
disease and complications or symptoms of liver disease (including varices, ascites, 
liver cirrhosis, liver cancer and liver transplantation) were diagnosed and regis-
tered in 11% of CHC patients. Overall, 14.4% of all CHC patients had a co-infection 
with hepatitis B or HIV compared with 0.3% in the matched general population 
controls. The prevalence of psychiatric disorder, vascular, circulatory, and meta-
bolic disease were significantly higher in CHC patients compared with the general 
population controls. conclusions: Our CHC prevalence was lower than previously 
reported. Patients with CHC had notably increased risk of other diseases compared 
to matched general population controls.
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outCome researCH to investigate tHe aCtual status oF mrsa 
inFeCtion and usage oF anti-mrsa drugs in real CliniCal settings in 
JaPan : a retrosPeCtive dataBase study
Yuasa A1, Ii Y1, Yamamoto Y2, Kitazaki S2, Saito K1, Fujimoto Y1
1Pfizer Japan Inc, Tokyo, Japan, 2MinaCare co.ltd, Tokyo, Japan
oBjectives: To provide real-world evidence from a Japanese healthcare database 
on the status of MRSA infections and the usage of anti-MRSA drugs in actual 
clinical settings. The overall medical treatment of MRSA patients was also inves-
tigated. Methods: This was a retrospective study based on claims data from 
a Japanese healthcare database composed of annual health check and claims 
from approximately 2.3 million members of employment-based health insurance 
groups and their dependents. The data of patients who had at least one record of 
being diagnosed with an MRSA infection (U80.1 in ICD-10/v2010) and being pre-
scribed anti-MRSA drugs approved in Japan were extracted from the 2014 database. 
An adult patient was defined as 15 years of age or older. results: We identified 
patients (35.6% female, 77.7% adult) with an infection episode matching our defi-
nition. Among the 484 infection episodes, the top 3 infections were bacteremia 
(34.9%), pneumonia (19.6%), and surgical site infections (SSI) (7.2%). The site of 
infection was unknown in 29.8% of the patients. During the first month of the 
episode, Vancomycin, Teicoplanin, and Linezolid were prescribed in 72.9%, 16.9%, 
and 12.2% of patients, respectively. Compliance with the recommendations (drugs 
in A-I/A-II categories) of the latest Japanese MRSA treatment guidelines was fol-
lowed in 77.3%, 93.8%, and 89.7% of adult patients with bacteremia, pneumonia, 
and SSI, respectively. Blood culture tests were conducted in 54.7%, 37.0%, and 
27.6% of the adult episodes of bacteremia, pneumonia, and SSI. conclusions: 
This is the first investigation to look at the actual status of MRSA infection using 
insurance claims data. It was found that the compliance with the Japanese MRSA 
treatment guidelines were generally high. However, utilization rate of blood culture 
test was low, even for the bacteremia patients. Further investigation is needed 
to determine the reason for this in order to ensure accurate diagnosis of MRSA 
infections in the future.
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CoPing WitH disCrePanCies in ePidemiologiCal data From various 
sourCes For loW-inCidenCe diseases: tHe Case oF multidrug-
resistant tuBerCulosis in germany
Yates N, Leisten M, Huschens S, Wirth D
Janssen-Cilag GmbH, Neuss, Germany
oBjectives: Multidrug-resistant tuberculosis (MDR-TB) is designated an orphan 
disease in Germany, with less than 100 patients per year. TB case reporting has 
been obligatory since 2001 due to the Protection against Infection act (IfSG). The 
objective of this study was to compare the incidence of MDR-TB from different 
epidemiological data sources in Germany with data collected by the Robert-Koch-
Institute (RKI) according to the legal requirement. Methods: The following poten-
tial sources of epidemiological data of MDR-TB in Germany (for the year 2012) were 
searched: a systematic review of the literature, data from a statutory sickness fund 
(SHI) and data from the Federal Office of Administration (BVA) used for the risk 
adjustment scheme (Morbi-RSA) in the social health insurance system. Data from 
these sources were then compared with those collected by the RKI. results: The 
systematic literature review provided 445 relevant abstracts which were screened 
by two independent reviewers. Selection of 16 possible full text papers revealed no 
relevant publications on MDR-TB in Germany. Data from sickness funds as well 
as the BVA also showed no reported cases of MDR-TB, although both gave indica-
tions on the incidence of drug-sensitive TB (91 cases/100,000 & 52 cases/100,000, 
respectively). The data provided by the RKI reported 4,187 cases of TB (incidence: 
5.2 cases/100,000) of which 65 cases (2.3%) were MDR-TB. conclusions: Two 
factors are most striking: reports specific to MDR-TB are generally hard to find in 
SHI databases due to a lack of specific ICD-10 codes, but can be approximated with 
ICD-10 codes for drug-sensitive TB plus medication use. Furthermore, informa-
tion on TB incidence differs widely among the various data sources in Germany, 
possibly due to the different ways in which data are collected.
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tHe use oF single-arm evidenCe in tHe ComParative eFFiCaCy oF 
interFeron-Free antivirals For treatment-naïve HePatitis C 
genotyPe 1
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1University of British Columbia, Vancouver, BC, Canada, 2Redwood Outcomes, Vancouver, BC, 
Canada, 3Stanford University, Stanford, CA, USA
oBjectives: Single-arm trials have played a major role in assessing the efficacy 
of interferon-free antiviral regimens for hepatitis C genotype 1. To facilitate evi-
dence synthesis, we have devised methods to integrate single-arm evidence into 
the network meta-analysis (NMA) framework to indirectly compare interferon-free 
and interferon-containing antiviral regimens. Methods: We conducted a system-
